Core Laboratories N.V. (CLB) Tops Q2 EPS by 1c, Offers Guidance

Core Laboratories N.V. (NYSE: CLB) reported Q2 EPS of $1.35, $0.01 better than the analyst estimate of $1.34. Revenue for the quarter came in at $267.6 million versus the consensus estimate of $269.7 million.

Core Laboratories N.V. sees Q3 2014 EPS of $1.49-$1.52, versus the consensus of $1.52. Core Laboratories N.V. sees Q3 2014 revenue of $280-290 million, versus the consensus of $284.6 million.

Core Laboratories N.V. sees Q4 2014 EPS of $1.56-$1.61. Core Laboratories N.V. sees Q4 2014 revenue of $285-295 million.

For earnings history and earnings-related data on Core Laboratories N.V. (CLB) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Aspire Biopharma to acquire automotive supplier for $30 million
• Schwab's May activity shows margin loans nearly double